TNNI3 and breast cancer: A previous study revealed that breast cancer patients who received DOX treatment with elevated levels of cardiac troponin I (cTnI) exhibited higher circulating miR-1 levels than those who did not (78), while the levels of miR-133b,−146a,−208a/b and−423-5p did not show any significant difference in response to DOX treatment.